Subscribe To

Price Alert Latest News Economic Calendar News

HLN-WI / Haleon raises revenue guidance after bumper first half

Haleon PLC (LSE:HLN, NYSE:HLN), the spin-out from GSK PLC (LSE:GSK, NYSE:GSK) in which American giant Pfizer also has a significant stake, on Wednesday emulated its erstwhile parent by raising its revenue guidance. The consumer healthcare group, which listed in London and New York last week with a value of around £30bn, said it expects the top line to grow by between 6% and 8% this year, an increase to the range of two percentage points. Read More

Demo Live Account See Partner Details

Content Topics

Haleon

Raises

Revenue

Guidance

After

Bumper

First

Half

Stock

HLN-WI

Posted: Jul 27 2022, 03:35

Author Name: Proactive Investors

HLN-WI News

By Invezz
May 16, 2023

Haleon share price has stalled: is HLN a good buy now?

Haleon (LON: HLN) share price has moved sideways in the past few days as GlaxoSmithKline (GSK) continued selling stake in the company. The shares also

By Proactive Investors
May 3, 2023

Haleon profits grow more slowly after mushrooming costs over past year

Haleon PLC (LSE:HLN, NYSE:HLN) has grown profits more slowly in the first quarter of 2023 amid higher costs and unhelpful currency swings. The Volatro

By Proactive Investors
April 19, 2023

Haleon profit margin may disappoint, says Barclays

Haleon PLC (LSE:HLN, NYSE:HLN) has "achievable" sales targets but it may struggle to meet the market's expected level of profit margins, according to

By Proactive Investors
March 6, 2023

Haleon: difficult for shares to get significant re-rating says analyst

Haleon PLC (LSE:HLN, NYSE:HLN) will find it difficult to get a significant re-rating for its shares, reckons Deutsche Bank. Following a meeting wi

By Proactive Investors
March 2, 2023

Haleon falls to near 3m low as analysts blame 'technical factors'

Haleon PLC (LSE:HLN, NYSE:HLN) shares fell to close to a three-month low after the consumer health group posted encouraging full-year numbers but ana

By Proactive Investors
March 2, 2023

Haleon proposes first dividend as cash enables faster deleverage than expected

Haleon PLC (LSE:HLN, NYSE:HLN) declared an inaugural dividend after its merger from GSK last year as price increases and efficiencies enabled increase

By Proactive Investors
February 1, 2023

Haleon's reported strategic M&A dismissed as 'highly unlikely' and unwanted headache

Haleon PLC's (LSE:HLN, NYSE:HLN) reported interest in large 'strategic scale' acquisitions, such as with Sanofi's consumer arm, have been panned by

By Proactive Investors
December 7, 2022

Haleon upgraded by Barclays after Zantac litigation dismissed

Barclays has upgraded its rating on Haleon PLC (LSE:HLN, NYSE:HLN) after Zantac-related litigation in the US was dismissed, meaning it will not proc

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.